Added to YB: 2026-01-21
Pitch date: 2025-12-19
MIST [bullish]
Milestone Pharmaceuticals Inc.
-20.75%
current return
Author Info
Alpha Talon Investment Research is a Hong Kong–based private family office deploying only proprietary capital across biotech, value turnarounds, and catalyst-driven shorts, focused on intrinsic value, regulatory odds, and mispriced fundamentals. Sign up for the newsletter.
Company Info
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada.
Market Cap
$208.2M
Pitch Price
$2.12
Price Target
15.00 (+793%)
Dividend
N/A
EV/EBITDA
-3.24
P/E
-2.61
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Milestone Pharmaceuticals (NASDAQ MIST): From Regulatory Success to Commercial Proof
MIST: Single-asset specialty pharma w/ CARDAMYST (1st FDA-approved self-administered PSVT therapy in 30+ yrs) approved Dec 2025. Addresses $2B+ market inefficiency by moving treatment from ED to patients. 60-rep launch targets electrophysiologists/cardiologists. Bear case: limited adoption, negative FCF. Base: ~$200M rev by yr5, EBITDA+ by yr4. Bull: ~$340M rev, early leverage. Risk-adjusted equity value ~$770M (~$7-8/share). AFib-RVR expansion adds optionality. Key risks: adoption velocity, payer access friction. Clean asset-light model, patents to 2042.
Read full article (44 min)